Date | Price Target | Rating | Analyst |
---|---|---|---|
2/28/2024 | Outperform | Evercore ISI | |
2/27/2024 | $18.00 | Overweight | Morgan Stanley |
2/27/2024 | $26.00 | Buy | BofA Securities |
BURLINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-founder and Chief Executive Officer of the Company, will present at two upcoming investor conferences. Details of the presentations can be found below. Morgan Stanley Global Healthcare Conference Format: Fireside Chat Date: 09/06/2024 Time: 10:45 AM ET H.C. Wainwright 26th Annual Global Investment Conference Format: Company Presentation Date: 09/09/2024 Time: 2:00 PM ET Webcast replays will
Updated clinical results from German Real-World Registry demonstrate potential for Revita® to meaningfully sustain weight loss and lower blood sugar for at least one-year post-treatment in a real-world setting Granted U.S. FDA Breakthrough Device designation for Revita in weight maintenance after discontinuation of GLP-1 based drugs REMAIN-1 pivotal study for Revita in weight maintenance now initiated with anticipated data readouts beginning in Q4 2024 REVITALIZE-1 on-track to report topline data in mid-2025 in expanded Type 2 Diabetes patient population Presented head-to-head preclinical data comparing Rejuva® versus semaglutide in #1 abstract at ADA 2024 Conference call today at 4:30
Median weight decreased from 111 kilograms (245 pounds) to 97 kilograms (214 pounds), representing nearly 13% total body weight loss at 12 months in a hard-to-treat patient population living with obesity and Type 2 Diabetes Median HbA1c also decreased substantially from 9.6% to 7.2% at 12 months in these individuals who remained poorly controlled despite multiple glucose-lowering medications and advanced T2D Real-world results demonstrate potential for Revita to meaningfully sustain weight loss and lower blood sugar for at least one-year post-treatment Additional registry data from a larger number of patients will be presented at a scientific congress later this year BURLINGTON, Mass., A
BURLINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the second quarter 2024 and provide business updates on Wednesday, August 14, 2024, at 4:30 p.m. ET. A live webcast of the conference call can be accessed in the "Events" section of Fractyl's website at https://ir.fractyl.com/. The webcast will be archived and available for replay following the live event. About Fractyl Health Fractyl Health is a metabolic therapeutics company focused on pioneering new
Breakthrough Device Designations are granted by the U.S. FDA to expedite review of promising technologies that address high unmet needs and may improve the lives of people with life-threatening or debilitating conditions REMAIN-1 pivotal study underway to accelerate pathway for weight maintenance indication for Revita®, with anticipated data readouts beginning in Q4 2024 BURLINGTON, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches that treat the root cause of obesity and type 2 diabetes (T2D), today announced that the U.S. Food and Drug Administration (FDA) has granted Br
BURLINGTON, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced that Dr. Harith Rajagopalan, CEO of Fractyl Health, and Dr. Timothy Kieffer, CSO of Fractyl Health, will participate in a virtual fireside chat at the upcoming Piper Sandler 2nd Annual Virtual Obesity Day on Wednesday, June 26, 2024 at 9:30 a.m. EDT. The Company will discuss the acceleration of its weight maintenance clinical study, which it recently announced, as well as the recent preclinical data it presented at the American Diabetes Associati
Company will accelerate Revita® weight maintenance clinical study REMAIN-1; open label data from REVEAL-1 cohort expected in Q4 2024 and mid-point data analysis for REMAIN-1 anticipated in Q2 2025 Company expands Revita type 2 diabetes clinical study REVITALIZE-1, expanding eligibility; increases potential U.S. treatment population for Revita by over 6x (from ~4 to ~25 million patients) Company presented preclinical data showing greater, more durable weight loss for its GLP-1 pancreatic gene therapy Rejuva® vs. semaglutide in one of eight President Select Abstracts at the American Diabetes Association's 84th Scientific Sessions BURLINGTON, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Fract
Single administration of Rejuva reduced fat mass and improved glycemia in the well-validated diet-induced obesity (DIO) mouse model Rejuva also prevented weight and glycemic rebound after semaglutide withdrawal Data provide first demonstration that Rejuva treatment has potential to mimic natural release of GLP-1 from pancreas BURLINGTON, Mass., June 23, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today presented new data from its preclinical Rejuva pancreatic gene therapy program in an oral presentation at the American Diabetes As
BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced that it will present new preclinical obesity data from its pancreatic gene therapy platform, Rejuva, at the upcoming American Diabetes Association (ADA)'s 84th Scientific Sessions taking place June 21-24, 2024 in Orlando, FL. The abstract, "Single-Dose GLP-1-Based Pancreatic Gene Therapy Durably Maintains Body Composition and Glycemia after Semaglutide Withdrawal in a Murine Model of Obesity" was recognized as noteworthy and selected by the Scient
Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42% (p<0.01) and liver triglycerides by 67% (p<0.0001) compared to placebo two months after administration Data also demonstrated reductions of 36% in total cholesterol and 51% in low density lipoprotein (LDL) cholesterol (both, p<0.0001) compared to placebo two months after administration New results highlight potential for profound, durable, and broad metabolic benefit that can be achieved from single-administration GLP-1-based pancreatic gene therapy BURLINGTON, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company
Evercore ISI initiated coverage of Fractyl Health with a rating of Outperform
Morgan Stanley initiated coverage of Fractyl Health with a rating of Overweight and set a new price target of $18.00
BofA Securities initiated coverage of Fractyl Health with a rating of Buy and set a new price target of $26.00
SC 13G - Fractyl Health, Inc. (0001572616) (Subject)
144 - FRACTYL HEALTH, INC. (0001572616) (Subject)
8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)
10-Q - FRACTYL HEALTH, INC. (0001572616) (Filer)
8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)
8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)
10-Q - FRACTYL HEALTH, INC. (0001572616) (Filer)
8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)
10-K - FRACTYL HEALTH, INC. (0001572616) (Filer)
8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)
8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)
4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)
3/A - FRACTYL HEALTH, INC. (0001572616) (Issuer)
4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)
3 - FRACTYL HEALTH, INC. (0001572616) (Issuer)
BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced the appointment of Adrian Kimber as Chief Commercial Officer. Mr. Kimber joins Fractyl with over two decades of experience in the biotechnology and medical devices sectors. Throughout his career, he has showcased a commendable history of introducing groundbreaking therapies to worldwide markets. Renowned for his adeptness in formulating go-to-market strategies, assembling and leading commercial teams, and implementing operational excellence, he
LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) ("Fractyl Health" or the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of Type 2 Diabetes (T2D) and obesity, today announced the appointment of Samuel Conaway to its Board of Directors. Mr. Conaway's extensive background in the commercialization of medical technologies and leadership in new product launches will provide valuable insight and experience as Fractyl Health advances through pivotal clinical studies for T2D and weight loss maintenance and continues its ongoing pilot launch and real-world registry study of Revita in Germany. "Sam Conaway's
Updated clinical results from German Real-World Registry demonstrate potential for Revita® to meaningfully sustain weight loss and lower blood sugar for at least one-year post-treatment in a real-world setting Granted U.S. FDA Breakthrough Device designation for Revita in weight maintenance after discontinuation of GLP-1 based drugs REMAIN-1 pivotal study for Revita in weight maintenance now initiated with anticipated data readouts beginning in Q4 2024 REVITALIZE-1 on-track to report topline data in mid-2025 in expanded Type 2 Diabetes patient population Presented head-to-head preclinical data comparing Rejuva® versus semaglutide in #1 abstract at ADA 2024 Conference call today at 4:30
BURLINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the second quarter 2024 and provide business updates on Wednesday, August 14, 2024, at 4:30 p.m. ET. A live webcast of the conference call can be accessed in the "Events" section of Fractyl's website at https://ir.fractyl.com/. The webcast will be archived and available for replay following the live event. About Fractyl Health Fractyl Health is a metabolic therapeutics company focused on pioneering new
Initiation of Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 based drugs expected in the second half of 2024 Topline data from Revitalize-1 pivotal study in patients with inadequately controlled T2D anticipated in the fourth quarter 2024 Update from real-world Germany registry study of Revita in patients with T2D at DDG Annual Meeting Appointed Adrian Kimber as Chief Commercial Officer to lead Revita launch readiness activities Conference call today at 4:30 p.m. ET BURLINGTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new appro
BURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced it will report financial results for the first quarter 2024 and provide business updates after market close on Monday, May 13, 2024. The Company's management will host a conference call on the same day beginning at 4:30 p.m. ET. A live webcast of the conference call can be accessed in the "Events" section of Fractyl's website at www.ir.fractyl.com. The webcast will be archived and available for replay following the live event. About Fractyl Healt
Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches that treat the root cause of obesity and type 2 diabetes (T2D), today announced that it will accelerate its REMAIN-1 clinical study, which is evaluating Revita's efficacy in maintaining weight loss following the discontinuation of GLP-1 therapy. The Company also announced that the U.S. Food and Drug Administration (FDA) has approved an amendment to the protocol for the REVITALIZE-1 study of its Revita device, which expands eligibility to patients with T2D who are inadequately controlled on any glucose lowering agent, including GLP-1 agonists and/or insulin, thus expanding
Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today presented new data from its preclinical Rejuva pancreatic gene therapy program in an oral presentation at the American Diabetes Association (ADA)'s 84th Scientific Sessions in Orlando, FL. The presentation titled "Single-Dose GLP-1-Based Pancreatic Gene Therapy Durably Maintains Body Composition and Glycemia After Semaglutide Withdrawal in a Murine Model of Obesity," and was chosen as noteworthy and one of eight President's Select Abstracts at ADA this year. Rejuva is the Company's adeno-associated virus (AAV)
Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today presented new data from its preclinical Rejuva pancreatic gene therapy program in an oral presentation at the American Diabetes Association (ADA)'s 84th Scientific Sessions in Orlando, FL. The presentation titled "Single-Dose GLP-1-Based Pancreatic Gene Therapy Durably Maintains Body Composition and Glycemia After Semaglutide Withdrawal in a Murine Model of Obesity," and was chosen as noteworthy and one of eight President's Select Abstracts at ADA this year. Single administration of Rejuva reduced fat mass and
Gainers Venus Concept (NASDAQ:VERO) stock rose 131.0% to $1.43 during Thursday's after-market session. The market value of their outstanding shares is at $9.0 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares increased by 8.58% to $2.15. The market value of their outstanding shares is at $3.1 million. Applied DNA Sciences (NASDAQ:APDN) stock moved upwards by 8.27% to $0.59. The market value of their outstanding shares is at $6.0 million. Kiora Pharmaceuticals (NASDAQ:KPRX) shares rose 5.0% to $0.45. The market value of their outstanding shares is at $11.9 million. Fractyl Health (NASDAQ:GUTS) shares moved upwards by 4.94% to $6.79. The market value of their outstanding shares is at
Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), presented new data from its preclinical Rejuva pancreatic gene therapy program as part of an oral presentation (abstract number 4029196) on Sunday, May 19th, at Digestive Disease Week (DDW) 2024 in Washington, D.C.
Fractyl Health (NASDAQ:GUTS) reported quarterly losses of $(0.17) per share. This is a 97.84 percent increase over losses of $(7.87) per share from the same period last year. The company reported $33.000 thousand in sales this quarter. This is a 560.00 percent increase over sales of $5.000 thousand the same period last year.
Fractyl Health (NASDAQ:GUTS) reported $33.000 thousand in sales this quarter. This is a 560.00 percent increase over sales of $5.000 thousand the same period last year.
First 14 participants with at least six months of follow up continue to demonstrate sustained improvements in blood glucose and weight with reduction in T2D medication utilization after a single Revita treatment. No device- or procedure-related serious adverse events have been observed to date in any registry participant.
Shares of Cal-Maine Foods, Inc. (NASDAQ:CALM) rose sharply in today’s pre-market trading after the company reported upbeat results for its fourth quarter. The company reported quarterly earnings of $3.00 per share which beat the analyst consensus estimate of $2.46 per share, according to data from Benzinga Pro. Cal-Maine Foods shares jumped 8.3% to $63.80 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers LAMF Global Ventures Corp. I (NASDAQ:LGVC) rose 148.9% to $26.79 in pre-market trading. ViewLAMF Global Ventures Corp. I shareholders approved previously announced business combination with Nuvo Group Ltd. Aesthetic Medical International Holdings
U.S. stock futures were lower this morning, with the Nasdaq futures falling by around 0.2% on Wednesday. Shares of Intel Corporation (NASDAQ:INTC) fell sharply in today’s pre-market trading after the company outlined a new financial framework for its foundry business. After the market close on Tuesday, Intel announced a new financial reporting structure designed to drive increased cost discipline and higher returns by providing greater transparency, accountability and incentives across the business. Intel shares dipped 4.8% to $41.85 in pre-market trading. Here are some big stocks recording losses in today’s pre-market trading session. Mesoblast Limited (NASDAQ:MESO) shares tumbled